Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration
Biomolecules · 2024
DOI: 10.3390/biom14050575 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2024. Verfasst von Katarzyna Budzynska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL 60607, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Regeneration, Cell- and Tissue-Based Therapy, Muscle, Skeletal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Kosciuszko Foundation (KF) Special Grant, Polish-American Medical Society in Chicago (PAMS), Kosciuszko Foundation (KF) Special.
Abstract (Originalsprache)
Chimerism-based strategies represent a pioneering concept which has led to groundbreaking advancements in regenerative medicine and transplantation. This new approach offers therapeutic potential for the treatment of various diseases, including inherited disorders. The ongoing studies on chimeric cells prompted the development of Dystrophin-Expressing Chimeric (DEC) cells which were introduced as a potential therapy for Duchenne Muscular Dystrophy (DMD). DMD is a genetic condition that leads to premature death in adolescent boys and remains incurable with current methods. DEC therapy, created via the fusion of human myoblasts derived from normal and DMD-affected donors, has proven to be safe and efficacious when tested in experimental models of DMD after systemic–intraosseous administration. These studies confirmed increased dystrophin expression, which correlated with functional and morphological improvements in DMD-affected muscles, including cardiac, respiratory, and skeletal muscles. Furthermore, the application of DEC therapy in a clinical study confirmed its long-term safety and efficacy in DMD patients. This review summarizes the development of chimeric cell technology tested in preclinical models and clinical studies, highlighting the potential of DEC therapy in muscle regeneration and repair, and introduces chimeric cell-based therapies as a promising, novel approach for muscle regeneration and the treatment of DMD and other neuromuscular disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL 60607, USA.
- Chair and Department of Traumatology, Orthopaedics, and Surgery of the Hand, Poznan University of Medical Sciences, 61-545 Poznan, Poland.
ORCID-Profile: Katarzyna Budzynska, Maria Siemionow, Lucile Chambily
Förderung
- The Kosciuszko Foundation (KF) Special Grant
- Polish-American Medical Society in Chicago (PAMS)
- Kosciuszko Foundation (KF) Special
- Polish–American Medical Society in Chicago (PAMS)
Zitieren
APA
Budzynska, K., Siemionow, M., Stawarz, K., Chambily, L., & Siemionow, K. (2024). Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration. Biomolecules. https://doi.org/10.3390/biom14050575
Vancouver
Budzynska K, Siemionow M, Stawarz K, Chambily L, Siemionow K. Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration. Biomolecules. 2024. doi:10.3390/biom14050575
BibTeX
@article{Budzynska2024,
author = {Budzynska, Katarzyna and Siemionow, Maria and Stawarz, Katarzyna and Chambily, Lucile and Siemionow, Krzysztof},
title = {Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14050575}
}
EUVIMED